Skip to main content

Table 1 Cell-based therapies with mesenchymal stem cells for doxorubicin cardiomyopathy

From: Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears

Cell-based therapy hypothesis

Cell type/type of transplantation

Number of cells administered

Delivery route/ time of administration

Animal model

Doxorubicin treatment/ route of administration

Method of cardiac diagnosis

Increase in LVEF versus control (percentage)

References

Regeneration

BMMSC/autologous

1 × 107

Intracoronary/4 weeks after Dox treatment

Rabbit

2 mg/kg per week for 8 weeks/intraperitoneal

Echocardiography

3 (not significant)

[60]

Regeneration

BMMSC/autologous

1.5-2.0 × 106

Epimyocardial/2 weeks after Dox treatment

Rabbit

3 mg/kg for 6 weeks/intraperitoneal

Echocardiography

9 (P < 0.002)

[61]

Regeneration

BMMSC/heterologous

5 × 106

Intravenously/2 weeks after Dox treatment

Rat

Three doses of 2.5 mg/kg per week for 2 weeks/intraperitoneal

ND

 

[62]

Regeneration

BMMSC/ heterologous

5 × 106

Intravenously (one injection per day, 10 times)/ 10 weeks after Dox treatment

Rat

2.5 mg/kg per week for 6 weeks/intraperitoneal

Echocardiography

13 (P < 0.05)

[63]

Regeneration

hUCB/xenograft

2.5 × 106

Intravenously/2 week after Dox treatment

Mice

400 ng/kg per minute/oral

ND

 

[49]

Prevention

hUCB/xenograft

1 × 106

Intravenously/at the end of each Dox cycle

Mice

Three cycles of three doses of 2 mg/kg per week/intraperitoneal

Echocardiography

10 (P < 0.05)

[64]

Prevention

ASC/heterologous

3 × 106

Intravenously/3 days before Dox treatment

Rat

5 mg/kg per week for 4 weeks/intraperitoneal

Echocardiography

13 (not significant)

[65]

  1. ASC, adipose tissue-derived mesenchymal stem cell; BMMSC, bone marrow mesenchymal stem cell; Dox, doxorubicin; hUCB, mesenchymal stem cell from human umbilical cord blood; LVEF, left ventricular ejection fraction; ND, not determined